Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

2cureX continues its IP expansion by securing a patent on its IndiTreat test in Australia

2cureX AB (“2cureX”, NASDAQ: 2CUREX) is pleased to announce the granting of an Australian patent (AU2015283320A) on its key product, IndiTreat®. As previously communicated, 2cureX was granted a European patent (EP3164709) in August 2018, a US patent (US10,371,695) in November 2019 and a Hong Kong patent (HK1237870) in October 2019. These patents will be in force until July 2035.2cureX is currently preparing for the launch of IndiTreat in 2020. During this Pre-launch phase it is very important for customers/partners that the technology is clinically validated and protected by a strong patent

Farxiga granted FDA Priority Review for patients with heart failure with reduced ejection fraction

6 January 2020 07:01 GMT   Farxiga granted FDA Priority Review for patients with heart failure with reduced ejection fraction   AstraZeneca today announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure (HF) in adults with heart failure with reduced ejection fraction (HFrEF) with and without type-2 diabetes (T2D). Farxiga is a first-in-class, oral once-daily selective inhibitor of human

Invitation to the presentation of Gjensidige's results for the 4th quarter 2019

Gjensidige Forsikring Group (OSE:GJF) will publish the results for the 4th quarter 2019 on 22 January at 7.00 CET. 22 January (Oslo) 9.00 CET CEO Helge Leiro Baastad and CFO Jostein Amdal will present the results in a combined webcast and conference call. The presentation and following Q&A session will be held in English. The webcast can be viewed live on www.gjensidige.no/ir. Participants who would like to ask questions should dial in using one of the telephone numbers below. The full presentation can also be listened to live, using the same dial-in details. Dial-in details:

Lokelma approved in China for the treatment of adult patients with hyperkalaemia

6 January 2020 07:00 GMT   Lokelma approved in China for the treatment of adult patients with hyperkalaemia   Patients in China will benefit from Lokelma's rapid reduction of potassium in the blood and the sustained treatment effect   AstraZeneca's Lokelma (sodium zirconium cyclosilicate) has been approved in China for the treatment of adult patients with hyperkalaemia (elevated levels of potassium in the blood).  The approval by the National Medical Products Administration (NMPA) was based on positive results from the extensive Lokelma clinical trial programme

Warrant program 2017 fully utilized for subscription of shares

The company has received a total of 2,750,000 SEK in cash for the conversion of warrants to shares.The warrants pursuant to the warrant program resolved by the board on the 14 of November 2017, with authorization given by the general meeting, has been utilised in full. The company's share capital hereby increases by SEK 129,917.90 while the number of shares in the company increases by 1,897,444 which entails a dilution of 6.897 percent. The share capital will hereafter amount to SEK 1,006,820.09 while the number of shares amounts to 14,704,554 whereof 295,302 class A shares and 14,409,

BAKKAFROST: Purchase of treasury shares for the Share Savings plan

Reference is made to the announcement made on 3 January 2020 regarding Bakkafrost's allocation of free shares to employees participating in Bakkafrost's Share Savings Plan 2017. On 3 January 2020 Bakkafrost has purchased 9,500 Bakkafrost shares to be used as treasury shares for the Share Savings Plan for employees and to settle the allocation of free shares following the conclusion of the Share Savings Plan for 2017. The shares were purchased in the market at a price of NOK 668,50 per share. After the share purchase and settlement Bakkafrost holds 1,491 treasury shares. For further

Getinge completes acquisition of Applikon Biotechnology B.V.

Getinge has today completed the previously announced acquisition of 100% of the shares in Applikon Biotechnology B.V. from Applikon Biotechnology Holding B.V..On December 20, 2019, Getinge announced an agreement to acquire Applikon Biotechnology B.V., a leading company in the development and supply of advanced bioreactor systems for the research and production of vaccines and antibodies in the biopharmaceutical industry, as well as enzymes and bio-plastics for industrial biotechnology. All conditions for the transaction and closing have now been fulfilled. The transaction was completed

Aker BP ASA announces that a series of investment grade fixed income investor calls will be arranged

Aker BP ASA (the “Company”) announced today that a series of investment grade fixed income investor calls will be arranged. A five year and/or ten year U.S. Dollar-denominated Rule 144A/Regulation S senior unsecured notes offering may follow, subject to market conditions. For further information, please contact: Ole-Johan Faret, Press Spokesman, tel.: +47 402 24 217 John Ole Hægeland, VP Corporate Finance, tel.: +47 906 06 169 Lars Mattis Hanssen, Senior IR Professional, tel.: +47 994 59 460 Cautionary Statements This press release is for information purposes only and does

FISKARS CORPORATION: ACQUISITION OF OWN SHARES 03.01.2020

Fiskars Corporation NOTIFICATION   03.01.2020 at 18:30 EET/EEST   FISKARS CORPORATION: ACQUISITION OF OWN SHARES 03.01.2020   Date 03.01.2020  Exchange transaction Buy  Share class FSKRS  Amount       1,000  Average price/share 11.8400 EURHighest price/share 11.8800 EURLowest price/share 11.7800 EURTotal price 11,840.00 EUR        The shares held by Fiskars Corporation on 03.01.2020:   FSKRS  410,677       On behalf of

United Bankers Corporation: Acquisition of Own Shares 03.01.2020

United Bankers Corporation NOTIFICATION   03.01.2020 at 18:30   UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 03.01.2020 Date 03.01.2020Exchange transaction BuyShare class UNIAVAmount 100Average price/share 9.0000 EURHighest price/share 9.0000 EURLowest price/share 9.0000 EURTotal price 900.00 EUR The shares held by United Bankers Corporation on 03.01.2020: UNIAV 38,460 On behalf of United Bankers CorporationSkandinaviska Enskilda Banken AB (Publ)   Antti

DNB ASA - Share buy-back status after week 1

During week 1 2020, DNB ASA has purchased 314 000 own shares at an average price of NOK 164.95 per share. After this, DNB ASA owns a total of 9 933 000 own shares. The repurchase of shares is part of the share buy-back programme announced by DNB ASA on 24 October 2019, as subsequently amended by an announcement on 20 November and 12 December 2019. The share buy-back programme comprises up to approximately 23.7 million shares, of which up to approximately 15.6 million shares may be repurchased in the open market. The rest will be redeemed from the state of Norway on a proportionate basis,

#20-3 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details see attached file. For further information concerning this NGM notice please contact: Listing on +46 8 566 390 20 or at listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

BAKKAFROST: Q4 2019 Trading Update

In Q4 2019 the harvest volumes for Bakkafrost’s operation in the Faroe Islands and Bakkafrost’s subsidiary in Scotland, The Scottish Salmon Company (SSC), were: Faroe Islands: 18.0 thousand tonnes · Farming North    0.0 thousand tonnes · Farming West   13.2 thousand tonnes · Farming South    4.8 thousand tonnes Scotland: 7.9 thousand tonnes The total harvest for 2019 in the Faroe Islands was 57.2 thousand tonnes gutted weight and in Scotland (SSC) the total harvest in 2019 was 33.8 thousand tonnes gutted weight. All harvest volumes are provided in head on gutted (HOG)

#20-2 Delisting of certain derivatives from NGM

Certain derivatives will be delisted from NGM.For more details see attached files. For further information concerning this NGM notice please contact: Listing department on +46 8 566 390 20 or at listings@ngm.se Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

The last conversion of convertible notes into shares, as part of the financing agreement announced January 22, 2019

The last outstanding conversion means that the financing scheme with convertibles is now completedThe number of convertible notes converted on January 3, 2020, was 12. The number of convertible notes remaining under the fourth tranche is 0. The number of shares and the number of votes before the conversion was 48 143 209. Through this conversion, and once the shares from the conversion will be registered at Bolagsverket, the number of shares and the number of votes shall have increased by 265 486. The total number of shares and total number of votes after this conversion and once the shares

Tikkurila Oyj: Notice pursuant to the Finnish Securities Markets Act, Chapter 9, Section 10

Tikkurila OyjMajor Shareholders AnnouncementJanuary 3, 2020 at 12.00 a.m. (CET+1) Notice pursuant to the Finnish Securities Markets Act, Chapter 9, Section 10 Tikkurila Oyj (business ID 0197067-4) has received a notification from FMR LLC on 2nd January, 2020, that with effect from 1st January 2020, Fidelity Management & Research Company has changed name to Fidelity Management & Research Company LLC. FMR Co., Inc, FIMM, and SelectCo have also merged into Fidelity Management & Research Company LL. Total positionsof person(s)subjectto thenotificationobligation:

Metsä Board Corporation: Managers’ transactions

Metsä Board Corporation Managers’ transactions 3 January 2020 at 12 noon EETMetsäliitto Cooperative, which is a closely associated party to Metsä Board’s chairman and two members of the Board, has acquired on 30 December 2019 Metsä Board Corporation’s B shares. Metsä Board Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Metsäliitto Osuuskunta Position: Closely associated person (X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer Name: Hämälä Ilkka Position:

ODI Pharma’s new share issue prior to listing significantly oversubscribed

The subscription period in ODI Pharma AB's ("ODI Pharma" or "Company") new share issue prior to listing on Spotlight Stock Market was completed on the 30th of December 2019. The interest was significant, and the Company today announces that the new share issue of a maximum of approximately SEK 25 million was subscribed to approximately 383 percent (incl. pre-subscription commitments), which means that ODI Pharma will receive approximately SEK 25 million before issue costs. The offering that was made available for the public (i.e. not incl. pre-subscription commitments), which represented

Expanding in-house technologies and services with Planmeca

Dr Ceri Owen-Roberts is the Principal of Elgin Park Dental Practice in Bristol, England. He has a particular interest in restorative dentistry and dental implants. In the following guest post, Dr Owen-Roberts explains how he came to equip his clinic with a Planmeca CBCT unit. With a focus on dental implants and oral surgery, I used to frequently refer my patients out to colleagues for CBCT scans. These are necessary for accurate diagnostics and treatment planning and offer greater visualisation than plain film. However, as my implant business grew, it was clear from the number of

Linn Andersson appointed as General Manager for Boliden Rönnskär

Linn Andersson appointed as General Manager for Boliden Rönnskär.Linn has extensive experience from leadership positions within Boliden, including as production manager as well as environmental manager at Boliden Rönnskär. She holds a master's degree in chemistry from Umeå University and a MBA from Edinburgh Business School. Linn assumes the role as General Manager at Boliden Rönnskär in the end of March 2020 at the latest.  For further information, please contact:Klas Nilsson, Director of Group Communications, tel: +46 (0)70 453 65 88

Terranet to Present First Serious Lidar Alternative at CES

At next week’s International CES 2020, Terranet will demonstrate VoxelFlow  - a 3D motion perception technology capable of detecting and classifying objects far more accurately and exponentially faster than Lidar. Terranet’s demo is timely considering Tesla CEO Elon Musk shocked the press just last April with his remarks: “Lidar is a fool’s errand. Anyone relying on lidar is doomed. Doomed!” In a bold move, Swedish-headquartered Terranet plans on backing up Musk’s claims that Lidar is merely a dangerous shortcut to image recognition – a perilous reliance if that’

A good production year 2019 at Fortum’s Loviisa nuclear power plant - production record at unit 1

FORTUM CORPORATION PRESS RELEASE 3 January 2020 Fortum’s Loviisa nuclear power plant had a good production year in 2019. The power plant generated a total of 8.2 terawatt hours (net) of carbon-free power equalling more than 10% of Finland’s total electricity production. Loviisa unit 1 achieved units' production record with 4.1 terawatt hours. As a result of the Loviisa nuclear power plant’s electricity production, Finland emits about 6 million tonnes less carbon dioxide emissions compared to the equivalent amount of fossil fuel-based electricity. On an international scale, the 92.4%

EQT invests in SHL Medical, a world-leading provider of drug delivery solutions

· EQT acquires minority stake in SHL Medical, a world-leading manufacturer of advanced drug delivery systems such as autoinjectors · SHL is a pioneer and technology frontrunner in the self-injection industry, promoting well-being for all by allowing patients to safely self-administer medications at home · EQT will support SHL and the management team in its next phase of growth and innovation by leveraging EQT’s healthcare expertise, local angles and digital capabilities The EQT VIII Fund (“EQT”) today announced that it has entered into an agreement to acquire a minority stake

There are no items matching the current filter
There are no more items matching the current filter
Back to top